Back to Search Start Over

75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6.

Authors :
Wainberg, Z.A.
Enzinger, P.C.
Qin, S.
Yamaguchi, K.
Gnanasakthy, A.
Taylor, K.
Jamotte, A.
Majer, I.
Kang, Y-K.
Source :
Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1460-S1461. 2p.
Publication Year :
2022

Subjects

Subjects :
*ESOPHAGOGASTRIC junction
*QUALITY of life
*PLACEBOS

Details

Language :
English
ISSN :
09237534
Volume :
33
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
160398021
Full Text :
https://doi.org/10.1016/j.annonc.2022.10.111
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details